Congress reviews patent policy amid concerns over prescription drug costs
What happened
Congress is reviewing the existing patent policy framework. The review addresses issues such as patent thickets, product hopping, and serial litigation, which can delay the entry of generic and biosimilar drugs.
From rstreet.org
Why it matters
Patents play a considerable role in determining prescription drug prices. The review examines how patents can be used to extend monopoly power and deter lower-cost generic drug entry, keeping name-brand prices high.
From rstreet.org
Who's involved
- CongressIs reviewing the existing patent policy framework.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- MedicareSpeculative
Patent reform might lower Medicare's operational costs by targeting high drug prices.
- Federal Trade CommissionSpeculative
Patent reform could align with the Federal Trade Commission's mandate against market monopolies.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Patent reform may strengthen FTC's power against drug monopoliesPatent reform could strengthen the Federal Trade Commission's ability to challenge drug monopolies.Possible
- Patent reform may lower Medicare's drug costsPatent reform could lower Medicare's drug costs by boosting generic competition.Possible
Keep exploring
The entities involved
-
Congress
US record label; imprint of Congress Record Corp.